MENU
OUR PRODUCTS
MOBILE APPS
GENERAL INFO
Help
© 2013-2026 All rights reserved. Tickeron Inc.
CVAC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

CVAC stock forecast, quote, news & analysis

CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people... Show more

Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)
Annualized Return+16%
VIEW DETAILSVIEW DETAILS
VIEW FOR FREEVIEW FOR FREE
Interact to see
Advertisement
A.I.Advisor
published price charts
View AI Trading With up to 80% Returns
View a ticker or compare two or three
Ask AI
VS
Compare
VS
Compare
Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)Swing Trader for Large Caps: Focusing on Intrinsic Value Metrics, 60 min, (FA)
Annualized Return+16%
VIEW DETAILSVIEW DETAILS
VIEW FOR FREEVIEW FOR FREE
Interact to see
Advertisement
Related Blogs
MDXG

Why Is MiMedx Group (MDXG) Stock Down -7.57% Today?

PRTA

EDIT vs PRTA: Gene-Editing Momentum Faces Neuroscience Stability

ABSI

Why Is Absci Corporation (ABSI) Stock Down -7.67% Today?

HRTX

Why Is Heron Therapeutics (HRTX) Stock Down 12% Today?

PTHS

Why Is Pelthos Therapeutics (PTHS) Stock Down -6.58% Today?

View all blogs related to
#Biotechnology
Interesting Articles

Where do I Find a Good Attorney for my Estate Needs?

What is Cost of Capital?

What is Form 2106-EZ: Unreimbursed Employee Business Expenses?

Who Created Ethereum?

What is IRS Publication 513, Tax Information for Visitors to the United States?

View all articles
A.I. Advisor
published General Information

General Information

a clinical-stage biopharmaceutical company developing tumour immunotherapy

Industry Biotechnology

Industry
N/A
Address
Friedrich-Miescher-Strasse 15
Phone
+49 707198830
Employees
1049
Web
https://www.curevac.com
CVAC stock forecast, quote, news & analysis